Astellas Pharma US, Inc. to Nominate Two Directors and Submit Proposal to Remove Remaining Four Directors of CV Therapeutics, Inc.
TOKYO--(BUSINESS WIRE)--Astellas Pharma Inc. today announced that its wholly owned subsidiary, Astellas US Holding, Inc., will nominate two directors for election to the Board of Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) and submit a stockholder proposal to remove the remaining four directors at the 2009 Annual Meeting.